|
|
(PQ11) Reversing exosome-mediated immune suppression - a novel strategy for cancer therapy
|
5R21CA205644-02
|
$202,439
|
$202,439
|
WHITESIDE, THERESA
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
|
|
(PQ5) Mitochondria in Leukemic Stem Cell Disease Progression
|
5R01CA205975-02
|
$386,619
|
$386,619
|
GHAFFARI, SAGHI
|
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
|
|
|
(PQ8) Genetically faithful murine models for studying disease progression in chronic lymphocytic leukemia
|
1R01CA216273-01
|
$701,924
|
$701,924
|
WU, CATHERINE
|
DANA-FARBER CANCER INST
|
|
|
(PQB3) CD4 T cell response to BCR-ABL-positive Leukemia
|
5R01CA185062-04
|
$312,304
|
$312,304
|
FARRAR, MICHAEL
|
UNIVERSITY OF MINNESOTA
|
|
|
(PQB5) Reconstruction of Evolutionary Networks using Cross-Sectional Genomic Data
|
5R01CA185486-04
|
$517,690
|
$258,845
|
RABADAN, RAUL
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
|
(PQC2) Localization as a determinant of cancer dormancy
|
5R01CA194596-03
|
$553,740
|
$553,740
|
LIN, CHARLES
|
MASSACHUSETTS GENERAL HOSPITAL
|
|
|
(PQD1) lmpact of cytotoxic and targeted therapy on clonal evolution of CLL
|
5R01CA184922-04
|
$553,684
|
$553,684
|
WU, CATHERINE
|
DANA-FARBER CANCER INST
|
|
|
0021.0001 CG 425 METAVIVOR
|
261200800001E
|
$319,219,481
|
$27,826
|
UNKNOWN, UNKNOWN
|
LEIDOS BIOMEDICAL RESEARCH, INC.
|
|
|
5-hydroxymethylcytosine in human cancer
|
5R01CA160965-06
|
$394,250
|
$197,125
|
PFEIFER, GERD
|
VAN ANDEL RESEARCH INSTITUTE
|
|
|
A cohort study among workers exposed to benzene in China
|
ZIA CP010120-02060
|
$169,821
|
$67,929
|
Rothman, Nat
|
DCEG (NCI)
|
|
|
A CROSS-SECTIONAL STUDY OF OCCUPATIONAL EXPOSURE TO TRICHLOROETHYLENE, CHROMOS
|
ZIA CP010121-10363
|
$11,686
|
$11,686
|
Lan, Qing
|
DCEG (NCI)
|
|
|
A Label-Free, Point-of-Care Platform to Diagnose Acute Promyelocytic Leukemia
|
5R01CA190843-03
|
$311,458
|
$155,729
|
SOHN, LYDIA
|
UNIVERSITY OF CALIFORNIA BERKELEY
|
|
|
A Mouse Model of DNMT3A-Associated Hematologic Malignancy
|
5R01CA183252-04
|
$533,845
|
$533,845
|
GOODELL, MARGARET
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
A Novel Oncogenic Role for Cdc20 Implications in Adult T Cell Leukemia Treatment
|
5R00CA183914-04
|
$254,171
|
$254,171
|
WAN, LIXIN
|
H. LEE MOFFITT CANCER CTR & RES INST
|
|
|
A Novel Positron Emission Tomography Strategy for Early Detection and Treatment Monitoring of Graft-versus-host Disease
|
5R01CA201719-02
|
$361,504
|
$180,752
|
GAMBHIR, SANJIV
|
STANFORD UNIVERSITY
|
|
|
A phase IIA trial for the safety and tolerability of CD24Fc in prophylaxis of graft vs host disease.
|
1R44CA221513-01
|
$1,017,478
|
$1,017,478
|
DEVENPORT, MARTIN
|
ONCOIMMUNE, INC.
|
|
|
A rapid spontaneous murine model of CN-AML
|
3R01CA196658-02S1
|
$234,525
|
$234,525
|
GRIMES, H.
|
CINCINNATI CHILDRENS HOSP MED CTR
|
|
|
A rapid spontaneous murine model of CN-AML
|
5R01CA196658-02
|
$575,500
|
$575,500
|
GRIMES, H.
|
CINCINNATI CHILDRENS HOSP MED CTR
|
|
|
A Role for KSHV in the Pathogenesis of Malignancies
|
ZIA SC 010356
|
$317,262
|
$31,726
|
Tosato, Giovanna
|
CCR (NCI)
|
|
|
AARP prospective study of diet and cancer
|
ZIA CP010196-03152
|
$703,174
|
$35,159
|
Sinha, Rashmi
|
DCEG (NCI)
|
|
|
Aberrant signaling in acute myeloid leukemia
|
3R01CA204396-02S1
|
$232,133
|
$232,133
|
KENTSIS, ALEX
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
|
Aberrant signaling in acute myeloid leukemia
|
5R01CA204396-02
|
$459,674
|
$459,674
|
KENTSIS, ALEX
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
|
Abramson Cancer Center Support Grant
|
3P30CA016520-41S1
|
$125,000
|
$6,250
|
DANG, CHI
|
UNIVERSITY OF PENNSYLVANIA
|
|
|
Abramson Cancer Center Support Grant
|
3P30CA016520-41S2
|
$62,491
|
$3,125
|
VONDERHEIDE, ROBERT
|
UNIVERSITY OF PENNSYLVANIA
|
|
|
Abramson Cancer Center Support Grant
|
5P30CA016520-41
|
$7,810,244
|
$390,512
|
VONDERHEIDE, ROBERT
|
UNIVERSITY OF PENNSYLVANIA
|
|
|
Activation of Proto-Oncogenes by Chromosomal Translocation
|
ZIA SC 010378
|
$380,330
|
$190,165
|
Aplan, Peter
|
CCR (NCI)
|
|
|
Adipocytes are Important Players in the Acute Lymphoblastic Leukemia Microenvironment
|
7R01CA201444-02
|
$396,181
|
$396,181
|
MITTELMAN, STEVEN
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
|
Adoptive T cell Therapy for Pediatric Leukemia
|
ZIA BC 011565
|
$776,399
|
$776,399
|
Fry, Terry
|
CCR (NCI)
|
|
|
Advanced development and validation of targeted molecular counting methods for precise and ultrasensitive quantitation of low prevalence somatic mutations
|
3R33CA192980-03S1
|
$77,458
|
$77,458
|
SALIPANTE, STEPHEN
|
UNIVERSITY OF WASHINGTON
|
|
|
Advanced development and validation of targeted molecular counting methods for precise and ultrasensitive quantitation of low prevalence somatic mutations
|
5R33CA192980-03
|
$375,858
|
$375,858
|
SALIPANTE, STEPHEN
|
UNIVERSITY OF WASHINGTON
|
|
|
Aging-associated alterations in adaptive landscapes and the evolution of leukemia
|
5R01CA180175-05
|
$344,920
|
$344,920
|
DEGREGORI, JAMES
|
UNIVERSITY OF COLORADO DENVER
|
|
|
Agricultural Cohort Consortium
|
ZIA CP010119-10537
|
$50,451
|
$10,090
|
Beane Freeman, Laura
|
DCEG (NCI)
|
|
|
Agricultural Health Study - Biomarkers of Exposures and Effects in Agriculture
|
ZIA CP010119-10527
|
$1,244,533
|
$248,907
|
Hofmann, Jonathan
|
DCEG (NCI)
|
|
|
ALL immunobiology and the bone marrow niche
|
ZIA BC 011295
|
$332,742
|
$332,742
|
Fry, Terry
|
CCR (NCI)
|
|
|
Alliance for Clinical Trials in Oncology Operations Center
|
3U10CA180821-04S1
|
$2,088,480
|
$313,272
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
|
Alliance for Clinical Trials in Oncology Operations Center
|
5U10CA180821-04
|
$11,145,123
|
$1,671,768
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
|
Allogeneic T cells Transduced with an Anti-CD19 Chimeric Antigen Receptor
|
ZIA BC 011415
|
$13,582
|
$9,100
|
Kochenderfer, James
|
CCR (NCI)
|
|
|
Ambient dioxin exposure and cancer risk in women (IWHS and AHS)
|
ZIA CP010125-10712
|
$56,170
|
$11,234
|
Jones, Rena
|
DCEG (NCI)
|
|
|
AML-MutationCounter, a tool to detect residual and recurrent leukemia
|
1R41CA213690-01
|
$220,087
|
$220,087
|
KAUFMANN, WILLIAM
|
ASYSTBIO LABORATORIES, LLC
|
|
|
Analysis of circulatory disease after low dose or low dose rate radiation exposur
|
ZIA CP010222-10738
|
$25,339
|
$25,339
|
Little, Mark
|
DCEG (NCI)
|
|
|
Analysis of TET2 function in acute leukemia
|
5K08CA181507-02
|
$180,036
|
$180,036
|
SHIH, ALAN
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
|
Analysis of the novel phenomenon of antibody-mediated fratricide in Acute Myeloid Leukemia
|
1F30CA217006-01
|
$39,139
|
$39,139
|
FATEHCHAND, KAVIN
|
OHIO STATE UNIVERSITY
|
|
|
Anatomic Pathology Residency Program
|
ZIE BC 011384
|
$1,094,457
|
$43,778
|
Barr, Frederic
|
CCR (NCI)
|
|
|
Anticancer peptide therapeutics
|
1R01CA219150-01
|
$353,419
|
$353,419
|
LU, WUYUAN
|
UNIVERSITY OF MARYLAND BALTIMORE
|
|
|
APPLYING ERROR-CORRECTED SEQUENCING TO DETECT MINIMAL RESIDUAL IN THE AAML 1031 STUDY
|
1R01CA211711-01
|
$388,615
|
$388,615
|
DRULEY, TODD
|
WASHINGTON UNIVERSITY
|
|
|
ARID5B and disparities of childhood leukemia
|
3U01CA176063-04S1
|
$99,290
|
$99,290
|
YANG, JUN
|
ST. JUDE CHILDREN'S RESEARCH HOSPITAL
|
|
|
ARID5B and disparities of childhood leukemia
|
5U01CA176063-04
|
$368,510
|
$368,510
|
YANG, JUN
|
ST. JUDE CHILDREN'S RESEARCH HOSPITAL
|
|
|
Assay Development for NSD1 Methyltransferase Inhibitor Discovery
|
5R01CA191077-03
|
$312,244
|
$312,244
|
KOLB, EDWARD
|
ALFRED I. DU PONT HOSP FOR CHILDREN
|
|
|
ASSESSING THE THERAPEUTIC WINDOW FOR FUTURE ANTI-NOTCH DIMERIZATION AGENTS
|
5R01CA163653-05
|
$311,165
|
$311,165
|
KOPAN, RAPHAEL
|
CINCINNATI CHILDRENS HOSP MED CTR
|
|
|
ATBC Lymphoma Studies
|
ZIA CP010195-10733
|
$23,111
|
$3,467
|
Berndt, Sonja
|
DCEG (NCI)
|
|
Total relevant funding to Leukemia for this search: $250,547,507
|
